# For [[toxoplasmosis]],<ref name="pmid12461021">{{cite journal |vauthors=Djurković-Djaković O, Milenković V, Nikolić A, Bobić B, Grujić J |title=Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii |journal=J. Antimicrob. Chemother. |volume=50 |issue=6 |pages=981–7 |date=December 2002 |pmid=12461021 |doi= 10.1093/jac/dkf251|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12461021}}</ref> the medication has antiparasitic and therapeutic effects.

 
# For [[malaria]], it is one of the two components (along with [[proguanil]]) in the drug [[Malarone]]. Malarone has fewer side effects and is more expensive than [[mefloquine]].<ref>[http://healthlink.mcw.edu/article/979237802.html  Malarone: New Malaria Medication With Fewer Side-effects] {{webarchive |url=https://web.archive.org/web/20060514041931/http://healthlink.mcw.edu/article/979237802.html |date=May 14, 2006 }}</ref> Resistance has been observed.<ref name="pmid12649236">{{cite journal |vauthors=Färnert A, Lindberg J, Gil P |title=Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports |journal=BMJ |volume=326 |issue=7390 |pages=628–9 |date=March 2003 |pmid=12649236 |pmc=151974 |doi=10.1136/bmj.326.7390.628 |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=12649236|display-authors=etal}}</ref>
